65,437 trials
Head and Neck Cancer · Precancerous Condition
Primary: 24-month Progression-free Survival — 64 percentage of participants
Opioid Dependence, on Agonist Therapy
Primary: Number of Patients Reporting Treatment-Emergent Adverse Events — 20; 21 participants
Pelvic Organ Prolapse (POP)
Primary: Palpability of the Restorelle Direct Fix Anterior and Posterior (A&P) — 30; 0; 0; 0 participants
TBI · Brain Injury
Primary: Average Urge to Cough (UTC) Following Administration of 200 Micro Mole Capsaicin Solution Concentration — 4.5 Units on a Borg scale
Benign Prostatic Hyperplasia
Primary: Percentage of Participants With Treatment Success — 84.9 percentage of participants
Hypercholesterolemia
Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT) Analysis — -16.3; -14.4; -50.6; -15.9 percent change — p=<0.0001
Heterozygous Familial Hypercholesterolemia
Primary: Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent--to--Treat (ITT) Analysis — -48.7; 2.8 percent change — p=<0.0001
Respiratory Insufficiency
Primary: Prevention of Damage and/or Occlusion of Endotracheal (ET) Tube During Use — 0; 1 participants
Neoplasms · Lymphoma, Non-Hodgkin
Primary: Number of Participants With Dose-Limiting Toxicities (DLT) — 0; 0; 2; 0 participants
Polycystic Kidney, Autosomal Dominant
Primary: Change From Baseline (CFB) in Total Kidney Volume (TKV) at Month 25 — 1686.38; 1418.96; 1487.48; 1670.33 centimeter cube (cm^3) — p=<0.0001
Schizophrenia · Psychotic Disorders
Primary: Brain Glycine Increments After Oral Glycine Administration Measured With MRS as Glycine/Total Creatine, Normalized to the Glycine Dose Administered (g/kg). — 393; 677…
Extragonadal Germ Cell Tumor · Ovarian Cancer · Teratoma
Primary: Confirmed Objective Response Rate (Complete and Partial Response) as Measured by RECIST Criteria After 2 Courses of Treatment — 3; 7 participants
Hepatitis C
Primary: Percentage of Genotype 1 Hepatitis C Virus (HCV)-Infected Treatment-naive Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) — 96.4 Percentage…
Placental Expulsion Time
Primary: The Principal Outcome of the Study is the Placental Expulsion Time. — 15.21; 5.23 minutes — p=<0.001
Multiple System Atrophy
Primary: Number of Adverse Events up to Six Months Post-treatment — 43; 0 Adverse events